{"id":16931,"date":"2025-04-08T14:47:32","date_gmt":"2025-04-08T14:47:32","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/blog\/exploring-new-paths-in-adc-development\/"},"modified":"2025-04-08T14:47:32","modified_gmt":"2025-04-08T14:47:32","slug":"exploring-new-paths-in-adc-development","status":"publish","type":"blog","link":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","title":{"rendered":"Exploring new paths in ADC development"},"content":{"rendered":"<p><span style=\"font-size: 18pt;\">Antibody-drug conjugates (ADCs) represent an important approach to targeted cancer therapy, combining the specificity of antibodies with the potent cytotoxicity of small-molecule drugs. Despite their promise, clinical ADC development has faced numerous challenges, including limited therapeutic windows and off-target toxicity. To address these challenges, we\u2019re now rethinking traditional approaches and shifting our focus from antibody-centric to payload-centric strategies.<\/span><\/p>\n<p>\u00a0<\/p>\n<h2><span style=\"font-size: 24pt;\"><strong>A Holistic Approach to ADC Development<\/strong><\/span><\/h2>\n<p><span style=\"font-size: 18pt;\">Historically, ADC development has largely centred around optimizing the antibody component and subsequently conjugating a cytotoxic payload\/linker combination. The assumption was that the specificity of the antibody would allow selective delivery the payload and this would translate directly to clinical tolerability. Whilst crucial, this focus has often overshadowed other equally important aspects, such as conjugation site and technique, sample heterogeneity, linker stability and, more recently, payload selection.<\/span><\/p>\n<p><span style=\"font-size: 18pt;\"><a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/integrated-drug-discovery\/antibody-drug-conjugates\/\" target=\"_blank\" rel=\"noopener\">A holistic approach to ADC development<\/a> recognizes the need to balance all components\u2014antibody, conjugation, linker, and payload\u2014to create a more effective and safer therapeutic agent. This involves refining antibody specificity and minimizing the biophysical impact of conjugation, whilst also designing linkers that are stable in circulation and facilitate efficient payload release at the disease site. And by optimizing how the linker is conjugated, we can enhance drug-to-antibody ratios (DARs) and sample homogeneity, ultimately improving the overall ADC therapeutic profile.<\/span><\/p>\n<p>\u00a0<\/p>\n<h2><span style=\"font-size: 24pt;\"><strong>A Shift from Antibody-Centric to Payload-Centric Thinking<\/strong><\/span><\/h2>\n<p><span style=\"font-size: 18pt;\">Whilst ADC research traditionally focussed on the antibody, recent insights indicate that the payload plays an equally crucial role in determining the efficacy and safety of ADCs. As these therapeutics evolve, we are witnessing a move from traditional cytotoxic payloads toward more mechanistically targeted agents with defined, specific modes of action, tailored toward certain patient populations. Indeed, in oncology, payload selection is becoming more meticulously aligned with the cancer type and disease context, ensuring maximum therapeutic impact with minimal collateral damage.<\/span><\/p>\n<p><span style=\"font-size: 18pt;\">Furthermore, a robust understanding of how the payload interacts with cellular mechanisms delivers a second level of selectivity and can also inform better decisions in linker design, conjugation chemistry, and dose optimization. This paradigm shift emphasizes the importance of selecting potent and targeted agents that are effective at low doses and aligned with the intended patient population.<\/span><\/p>\n<p>\u00a0<\/p>\n<h2><span style=\"font-size: 24pt;\"><strong>Key Take Away<\/strong><\/span><\/h2>\n<p><span style=\"font-size: 18pt;\">Incorporating a holistic and payload-centric perspective in ADC development not only broadens therapeutic possibilities but also addresses the limitations seen in earlier generations of ADCs. By evolving from an antibody-centric mindset, we are becoming better positioned to harness the full potential of ADC technology\u2014offering hope for more precise and effective treatments, for cancer and other diseases, in the future.<\/span><\/p>\n<p><span style=\"font-size: 18pt;\"><strong>\u00a0<\/strong><\/span><\/p>\n<h3><span style=\"font-size: 18pt;\"><strong>Read the next part in our ADC development blog series:<\/strong><\/span><\/h3>\n<p><span style=\"font-size: 14pt;\">Part 2: <a href=\"https:\/\/www.sygnaturediscovery.com\/news-and-events\/blog\/evolving-role-of-med-chem-in-adc-development\/\" target=\"_blank\" rel=\"noopener\">What\u2019s the Evolving Role of Medicinal Chemistry in ADC Development?<\/a><\/span><\/p>\n<p>\u00a0<\/p>\n<h3><strong><span style=\"font-size: 18pt;\">About the Authors<\/span><\/strong><\/h3>\n<p><span style=\"font-size: 18pt;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-18115 size-medium\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/04\/SDpodcast_web-11-e1744109146956-800x593.jpg\" alt=\"Picture of Allan Jordan, VP of Oncology Drug Discovery at Sygnature Discovery and Joshua Greally, ADC Lead and Business Development Associate for Drug Discovery Services at Sygnature Discovery, filming the podcast style video series: ADc Development for Sygnature's NewPath ADC series\" width=\"300\" height=\"222\"><span style=\"font-size: 18pt;\">Allan Jordan is Vice President Oncology Drug Discovery at Sygnature Discovery and Josh Greally is ADC Lead at Sygnature Discovery. Follow their <\/span><a style=\"font-size: 18pt;\" href=\"https:\/\/youtu.be\/eFpplhWH6Tk\" target=\"_blank\" rel=\"noopener\">ADC development series<\/a><span style=\"font-size: 18pt;\"> on YouTube to hear all their insights.<\/span><\/span><\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":8075,"template":"","category":[1409,820],"class_list":["post-16931","blog","type-blog","status-publish","has-post-thumbnail","hentry","category-adcs","category-modalites"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exploring new paths in ADC development - Sygnature<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exploring new paths in ADC development - Sygnature\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/\",\"name\":\"Exploring new paths in ADC development - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/antibody-drug-conjugates-adc-development-targeted-cancer-therapy.webp\",\"datePublished\":\"2025-04-08T14:47:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/antibody-drug-conjugates-adc-development-targeted-cancer-therapy.webp\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/antibody-drug-conjugates-adc-development-targeted-cancer-therapy.webp\",\"width\":800,\"height\":450,\"caption\":\"Graphique illustrant la plateforme NewPath ADC pour le d\u00e9veloppement de conjugu\u00e9s anticorps-m\u00e9dicament de nouvelle g\u00e9n\u00e9ration, combinant un ciblage de pr\u00e9cision et des strat\u00e9gies de charge utile haute performance.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/blog\\\/exploring-new-paths-in-adc-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exploring new paths in ADC development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exploring new paths in ADC development - Sygnature","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","og_locale":"fr_CA","og_type":"article","og_title":"Exploring new paths in ADC development - Sygnature","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","og_site_name":"Sygnature","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/","name":"Exploring new paths in ADC development - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/antibody-drug-conjugates-adc-development-targeted-cancer-therapy.webp","datePublished":"2025-04-08T14:47:32+00:00","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/antibody-drug-conjugates-adc-development-targeted-cancer-therapy.webp","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/antibody-drug-conjugates-adc-development-targeted-cancer-therapy.webp","width":800,"height":450,"caption":"Graphique illustrant la plateforme NewPath ADC pour le d\u00e9veloppement de conjugu\u00e9s anticorps-m\u00e9dicament de nouvelle g\u00e9n\u00e9ration, combinant un ciblage de pr\u00e9cision et des strat\u00e9gies de charge utile haute performance."},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/blog\/exploring-new-paths-in-adc-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Exploring new paths in ADC development"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog\/16931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/blog"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/blog\/16931\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/8075"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=16931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=16931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}